Literature DB >> 16109430

Cannabinoid signalling.

Dirk G Demuth1, Areles Molleman.   

Abstract

After their discovery, the two known cannabinoid receptors, CB(1) and CB(2), have been the focus of research into the cellular signalling mechanisms of cannabinoids. The initial assessment, mainly derived from expression studies, was that cannabinoids, via G(i/o) proteins, negatively modulate cyclic AMP levels, and activate inward rectifying K(+) channels. Recent findings have complicated this assessment on different levels: (1) cannabinoids include a wide range of compounds with varying profiles of affinity and efficacy at the known CB receptors, and these profiles do not necessarily match their biological activity; (2) CB receptors appear to be intrinsically active and possibly coupled to more than one type of G protein; (3) CB receptor signalling mechanisms are diverse and dependent on the system studied; (4) cannabinoids have other targets than CB receptors. The aim of this mini review is to discuss the current literature regarding CB receptor signalling pathways. These include regulation of adenylyl cyclase, MAP kinase, intracellular Ca(2+), and ion channels. In addition, actions of cannabinoids that are not mediated by CB(1) or CB(2) receptors are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16109430     DOI: 10.1016/j.lfs.2005.05.055

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  136 in total

1.  Effects of centrally administered endocannabinoids and opioids on orofacial pain perception in rats.

Authors:  Marek Zubrzycki; Anna Janecka; Andreas Liebold; Mechthild Ziegler; Maria Zubrzycka
Journal:  Br J Pharmacol       Date:  2017-08-30       Impact factor: 8.739

Review 2.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

3.  Structural determinants in the second intracellular loop of the human cannabinoid CB1 receptor mediate selective coupling to G(s) and G(i).

Authors:  X P Chen; W Yang; Y Fan; J S Luo; K Hong; Z Wang; J F Yan; X Chen; J X Lu; J L Benovic; N M Zhou
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

Review 4.  Adenosine-cannabinoid receptor interactions. Implications for striatal function.

Authors:  Sergi Ferré; Carme Lluís; Zuzana Justinova; César Quiroz; Marco Orru; Gemma Navarro; Enric I Canela; Rafael Franco; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors.

Authors:  Brian D Hudson; Terence E Hébert; Melanie E M Kelly
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 6.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

7.  Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.

Authors:  Amy K Dickason-Chesterfield; Stephanie R Kidd; Steven A Moore; John M Schaus; Bin Liu; George G Nomikos; Christian C Felder
Journal:  Cell Mol Neurobiol       Date:  2006-05-31       Impact factor: 5.046

8.  Diphenyl purine derivatives as peripherally selective cannabinoid receptor 1 antagonists.

Authors:  Alan Fulp; Katherine Bortoff; Yanan Zhang; Herbert Seltzman; James Mathews; Rodney Snyder; Tim Fennell; Rangan Maitra
Journal:  J Med Chem       Date:  2012-11-09       Impact factor: 7.446

9.  A novel near-infrared fluorescence imaging probe that preferentially binds to cannabinoid receptors CB2R over CB1R.

Authors:  Xiaoxi Ling; Shaojuan Zhang; Pin Shao; Weixia Li; Ling Yang; Ying Ding; Cong Xu; Nephi Stella; Mingfeng Bai
Journal:  Biomaterials       Date:  2015-04-28       Impact factor: 12.479

Review 10.  CB2 receptors in reproduction.

Authors:  M Maccarrone
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.